GHRP-6

Mechanism

GHS-R1a agonist with stronger hunger, cortisol, and prolactin effects than newer agents.

Reported effects

What sources associate with this compound. Reported categories, not outcomes we have graded — each would need its own citation and rung.

• Hunger and weight gain
• GH pulse
• Class comparison

Reconstitution

mass ÷ diluent = concentration; dose ÷ concentration = volume; volume × the syringe factor = units on the barrel (100 for U-100, 40 for U-40). Run your own numbers.

Half-life, storage & sport

Elimination half-life

2.5 +/- 1.1 hours (elimination); 7.6 +/- 1.9 minutes (distribution) (human, IV) — study. nine male healthy volunteers, Eur J Pharm Sci 2013, PMID 23099431.

Storage

Lyophilised: Stable at room temperature ~3 weeks; store desiccated below -18C. Reconstituted: 4C for 2-7 days; below -18C for future use; 0.1% HSA/BSA for long term; avoid freeze-thaw. — source. ProSpec technical datasheet. Supplier handling recommendation for research-grade lyophilate, not a per-compound stability study.

In sport (WADA 2026)

Prohibited, at all times — named S2.2.4 (GHRPs: GHRP-6). the list

The half-life on file is 2.5 h, measured intravenously. On the schedule this record states — twice daily — each dose has fallen to 3.6% of its own peak by the time the next is given. Nothing accumulates, and there is no loading phase to run.

The rise is not modelled and the axis is not a blood level. No absorption rate constant and no volume of distribution are on file, so each dose appears at full height the instant it is given, and the axis is percent of this compound's own peak.

Reported adverse effects

• Marked increase in appetite

  Very commononset: Post-injectionreported reversible

• Water retention

  Commononset: First weeksreported reversible

Literature on file 6

• review or editorial
  Growth hormone-releasing peptide (GHRP) (1998, cited 122x) graded on: indexed as "Review" - secondary literature, not a study — “Review”
• animal in vivo
  Growth Hormone-Releasing Peptides: Investigation of Their Secondary Structure, Thermal Stability, and Model Membrane Interactions. graded on: an animal model — read from the indexed abstract — “mice”
• animal in vivo
  Ghrelin impairs embryo development after ovarian hyperstimulation. graded on: an animal model — read from the indexed abstract — “mice”
• animal in vivo
  Growth Hormone-Releasing Peptide-6 (GHRP-6) Ameliorates Post-Infarct Ventricular Remodeling and Systolic Dysfunction in a Model of Permanent Coronary Ligation. graded on: an animal model — read from the indexed abstract — “rats”
• animal in vivo
  Growth hormone releasing peptide-6 (GHRP-6) ameliorates acute lung injury and its subsequent evolvement to interstitial fibrosis. graded on: an animal model — read from the indexed abstract — “mice”

Not graded

1 citation whose study design could not be read from the title. Left ungraded rather than guessed at.

• not graded
  The Ghrelin/GHSR-1a Axis Attenuates Preeclampsia-like Features with Decidual Macrophage Reprogramming and Improved Placental Remodeling

What is circulated not evidence 4

Claims passed around in community guides and vendor copy, recorded because they circulate — not because they are true. Each is shown with the page it was read from and what this record actually holds. Checked 2026-08-24.

• unverified community data dose ubiquitous nothing on file either way

  100 mcg per injection two to three times daily is circulated as the saturation dose, with a claim that higher amounts add nothing per bolus.

  The 100 mcg per injection dose is considered near the saturation dose — higher amounts don't meaningfully increase per-bolus GH output.

  On the record Dosing on file is 100-300 mcg daily; the multi-dose multiplier (up to 300 mcg per shot, three times daily) exceeds it, and no saturation-dose record exists.

  Source 1 · Source 2

• unverified community data benefit common agrees with the record

  The intense hunger is circulated as a deliberate bulking tool rather than a side effect.

  GHRP-6 spikes appetite harder than any other GHRP — that's a feature if you use it right.

  On the record Hunger and weight gain is on file as a benefit row; the reframing as a bulking strategy is community editorial.

  Source 1

• unverified community data timing ubiquitous nothing on file either way

  Injecting fasted and waiting 20-30 minutes before eating is circulated as necessary for the GH response.

  injecting on an empty stomach (at least 2 hours after eating) and waiting 20-30 minutes before consuming food

  On the record No food-timing record exists on file for GHRP-6.

  Source 1

• unverified community data stacking common nothing on file either way

  Stacking with CJC-1295 is circulated as 'the gold-standard GH-releasing stack' with synergistic output.

  GHRP-6 + GHRH analog (CJC-1295) is considered the gold-standard GH-releasing stack.

  On the record No stacking or co-administration record exists on file for GHRP-6.

  Source 1

Identity

PubChem CID 4345065 computed 3D conformer

Skeletal formulathe canonical depiction

Drawn by PubChem from CID 4345065, the identifier on this record.

Molecular weight

873.0

Molecular formula

C46H56N12O6

PubChem CID

4345065

InChI key

WZHKXNSOCOQYQX-UHFFFAOYSA-N

Sequence

HWAWFK

SMILES

CC(C(=O)NC(CC1=CNC2=CC=CC=C21)C(=O)NC(CC3=CC=CC=C3)C(=O)NC(CCCCN)C(=O)N)NC(=O)C(CC4=CNC5=CC=CC=C54)NC(=O)C(CC6=CN=CN6)N

InChI

InChI=1S/C46H56N12O6/c1-27(54-44(62)39(20-29-23-51-35-15-7-5-13-32(29)35)57-43(61)34(48)22-31-25-50-26-53-31)42(60)56-40(21-30-24-52-36-16-8-6-14-33(30)36)46(64)58-38(19-28-11-3-2-4-12-28)45(63)55-37(41(49)59)17-9-10-18-47/h2-8,11-16,23-27,34,37-40,51-52H,9-10,17-22,47-48H2,1H3,(H2,49,59)(H,50,53)(H,54,62)(H,55,63)(H,56,60)(H,57,61)(H,58,64)

Classified as

Ghrelin Receptor Agonismmechanism

This is the mechanism behind the compounds usually filed as secretagogues, and it explains why appetite effects appear in the same records as growth hormone effects rather than as an unrelated aside.

Subcutaneousroute

This is the route the reconstitution arithmetic assumes. Mass divided by diluent volume gives concentration, dose divided by concentration gives volume, and volume in mL multiplied by 100 gives units on a U-100 barrel: 5 mg in 2 mL is 2.5 mg/mL, and 0.25 mg comes out at 0.1 mL, which is 10 units.

Intravenousroute

A large share of the pharmacokinetic numbers attached to peptide records, half-life in particular, come from intravenous studies and often from animals. Those numbers describe an intravenous curve and do not transfer unchanged to a depot under the skin.

Also called

• GHRP-6
• growth hormone releasing peptide-6

Listed prices 128

What 72 shops we track listed for GHRP-6, read from their own public catalogues on 2026-09-14. We take no commission on these and they are not ranked by any payment — how vendors are scored.

Share this record